You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR SCOPOLAMINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Scopolamine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006399 ↗ Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease Completed Alzheimer's Association Phase 2 1999-09-01 The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00006399 ↗ Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease Completed Eisai Inc. Phase 2 1999-09-01 The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00006399 ↗ Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease Completed Pfizer Phase 2 1999-09-01 The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00006399 ↗ Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease Completed National Center for Research Resources (NCRR) Phase 2 1999-09-01 The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
NCT00055575 ↗ Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies Terminated National Institute of Mental Health (NIMH) Phase 2 2003-02-27 This study looks at the role of a specific brain chemical system in the mood and attention symptoms seen in major depression and bipolar disorders using functional brain imaging.
NCT00130026 ↗ Caffeine in the Prevention of Post-operative Nausea and Vomiting Completed Beth Israel Deaconess Medical Center N/A 2005-03-01 The objective of this study is to determine if caffeine 500 mg intravenously is efficacious when added to standard anti-emetic prophylaxis in the prevention of post-operative nausea and vomiting (PONV) in patients undergoing ambulatory surgery under general anesthesia.
NCT00369915 ↗ The Antidepressant Efficacy of the Anticholinergic Scopolamine Terminated National Institute of Mental Health (NIMH) Phase 2 2006-08-01 A previous study showed that the intravenous administration of scopolamine produces antidepressant effects. This study is designed to determine if other routes of administration of scopolamine produce antidepressant effects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Scopolamine

Condition Name

Condition Name for Scopolamine
Intervention Trials
Motion Sickness 12
Healthy 6
Postoperative Nausea and Vomiting 4
Nausea 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Scopolamine
Intervention Trials
Motion Sickness 15
Vomiting 12
Nausea 10
Depression 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Scopolamine

Trials by Country

Trials by Country for Scopolamine
Location Trials
United States 56
China 5
Israel 4
France 4
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Scopolamine
Location Trials
California 12
Texas 7
Ohio 4
Connecticut 4
Massachusetts 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Scopolamine

Clinical Trial Phase

Clinical Trial Phase for Scopolamine
Clinical Trial Phase Trials
Phase 4 15
Phase 3 11
Phase 2/Phase 3 2
[disabled in preview] 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Scopolamine
Clinical Trial Phase Trials
Completed 40
Recruiting 14
Unknown status 9
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Scopolamine

Sponsor Name

Sponsor Name for Scopolamine
Sponsor Trials
Repurposed Therapeutics, Inc. 11
National Institute of Mental Health (NIMH) 3
University of California, Los Angeles 3
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Scopolamine
Sponsor Trials
Other 67
Industry 33
NIH 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.